Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Page values for "Lisdexamfetamine"

From Pharmacopedia
More actions

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringLisdexamfetamine (dimesylate)
brandStringVyvanse, Elvanse (EU)
structureFile
classesList of String, delimiter: ,[[:Category:Psychostimulants|Psychostimulant]] [[:Category:Amphetamines|Amphetamine]] [[:Category:ADHD medicines|ADHD medicine]] [[:Category:Schedule II controlled substances|Schedule II controlled substance]]
mechanismString'"`UNIQ--vote-00000013-QINU`"' Once converted, dextroamphetamine acts by displacing dopamine and norepinephrine from presynaptic vesicles via VMAT-2 and reversing DAT and NET transport, the shared mechanism of all amphetamine-class agents'"`UNIQ--ref-00000014-QINU`"'.
usesString'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"'
starting_doseStringADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day
preparationsStringCapsules 10, 20, 30, 40, 50, 60, 70 mg; chewable tablets 10, 20, 30, 40, 50, 60 mg
fda_maxString70 mg/day
pill_idText
routesList of String, delimiter: ,Oral
onsetString1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells)
durationString10-12 hours (smoother profile than immediate-release amphetamine salts)
halflifeStringParent lisdexamfetamine <1 hour; dextroamphetamine 10-12 hours after release'"`UNIQ--ref-00000017-QINU`"'
bioavailabilityString~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"'
pregnancyStringLimited human data; the amphetamine class is associated with intrauterine growth restriction and neonatal withdrawal symptoms.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-00000019-QINU`"'